TriangleNCT03926143 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Approximately 3 years (from first study treatment until safety follow-up)
What was measured
Overall survival (OS) defined as the time from first treatment in this study until death from any cause. Data on survival were collected by the site. Time frame was reduced due to early termination of the study. Table reports Kaplan-Meier median with Brookmeyer-Crowley confidence intervals. Number (%) of participants with event: 5 (55.6%) and Number (%) of participants censored: 4 (44.4%).
Groups in this outcome
Anetumab Ravtansine
Adult participants with solid tumors who received anetumab-ravtansine treatment as monotherapy, or in combination with gemcitabine in an applicable Bayer-sponsored anetumab ravtansine study. 8 participants received anetumab ravtansine monotherapy and 1 participant received anetumab ravtansine in combination with gemcitabine. Pooled results were reported.
| Group | Source count |
|---|---|
| Anetumab Ravtansine | 9 |
Reported measurements
25th percentile
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Anetumab Ravtansine | 17.6 | Not reported | 6.9 | 34.1 | Not reported |
Median
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Anetumab Ravtansine | 34.1 | Not reported | 6.9 | NA | "Not applicable" indicates value cannot be estimated due to censored data. |
75th percentile
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Anetumab Ravtansine | NA | Not reported | 28.5 | NA | "Not applicable" indicates value cannot be estimated due to censored data. |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.9
- upper Limit
- 34.1
- value
- 17.6
- title
- 25th percentile
- categories
- measurements
- comment
- "Not applicable" indicates value cannot be estimated due to censored data.
- group Id
- OG000
- lower Limit
- 6.9
- upper Limit
- NA
- value
- 34.1
- title
- Median
- categories
- measurements
- comment
- "Not applicable" indicates value cannot be estimated due to censored data.
- group Id
- OG000
- lower Limit
- 28.5
- upper Limit
- NA
- value
- NA
- title
- 75th percentile
- denoms
- counts
- group Id
- OG000
- value
- 9
- units
- Participants
- description
- Overall survival (OS) defined as the time from first treatment in this study until death from any cause. Data on survival were collected by the site. Time frame was reduced due to early termination of the study. Table reports Kaplan-Meier median with Brookmeyer-Crowley confidence intervals. Number (%) of participants with event: 5 (55.6%) and Number (%) of participants censored: 4 (44.4%).
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Adult participants with solid tumors who received anetumab-ravtansine treatment as monotherapy, or in combination with gemcitabine in an applicable Bayer-sponsored anetumab ravtansine study. 8 participants received anetumab ravtansine monotherapy and 1 participant received anetumab ravtansine in combination with gemcitabine. Pooled results were reported.
- id
- OG000
- title
- Anetumab Ravtansine
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Approximately 3 years (from first study treatment until safety follow-up)
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice